Bevacizumab (RhuMAB-VEGF) In Hepatocellular Cancer For Patients With Unresectable Tumor (Without Invasion Of The Main Portal Vein Or Metastatic Disease) A Phase II Study
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 29 Feb 2016 Biomarkers information updated
- 08 Nov 2006 Status change
- 17 Aug 2005 New trial record.